Company / SG&A Expense
MoonLake Immunotherapeutics SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$42.0M
FY2025
5-year range
$18.0M / $42.0M
FY2021-FY2025
Trend
+38.4%
vs FY2024
Sector context
#169 of 213
Health Care
What the data says
MoonLake Immunotherapeutics's sg&a expense of $42M is lower than 79% of companies in the Health Care sector (FY2025). Increased from $22M to $42M over the past 2 years.
Based on SEC 10-K filings.
$42M in FY2025 with a 5-year CAGR of +230.9%.
Increased from $22M to $42M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +22.2%
- 5-Year CAGR
- +230.9%
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 213This company $42.0M Sector average $722.3M
▼
-94.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +230.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 38.4% year-over-year.
- Ranks #169 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $42.0M | +38.4% |
| FY2024 | $30.3M | +35.8% |
| FY2023 | $22.3M | -3.0% |
| FY2022 | $23.0M | +27.5% |
| FY2021 | $18.0M | +16965.6% |
| FY2020 | $105.8K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026